To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema

• Status: Recruiting
• Trial end date: 2022-10-28
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of brolucizumab in treatment of Chinese patients with visual impairment due to Diabetic Macular Edema.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Aflibercept

Criteria

Inclusion Criteria:

• Patients with type 1 or type 2 diabetes mellitus

• Visual impairment due to Diabetic Macular Edema

Exclusion Criteria:

• Any active intraocular or periocular infection or active intraocular inflammation

• Structural damage of the fovea

• Uncontrolled glaucoma

• Neovascularization of the iris

Other protocol-defined inclusion/exclusion criteria may apply.